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Oral anticoagulation (OAC) significantly reduces the risk of stroke in patients with atrial fibrillation (AF). 
However, many AF patients on long-term anticoagula-
tion undergo procedures that require temporary interrup-
tion of OAC.1,2 Some have advocated that patients receive 
short-acting anticoagulants during these temporary interrup-
tions to “bridge” the patient and to potentially reduce the risk 
Background—Temporary interruption of oral anticoagulation for procedures is often required, and some propose using 
bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical 
practice are unknown.
Methods and Results—The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry is a 
prospective, observational registry study of US outpatients with atrial fibrillation. We recorded incident temporary interruptions 
of oral anticoagulation for a procedure, including the use and type of bridging therapy. Outcomes included multivariable-
adjusted rates of myocardial infarction, stroke or systemic embolism, major bleeding, cause-specific hospitalization, and death 
within 30 days. Of 7372 patients treated with oral anticoagulation, 2803 overall interruption events occurred in 2200 patients 
(30%) at a median follow-up of 2 years. Bridging anticoagulants were used in 24% (n=665), predominantly low-molecular-
weight heparin (73%, n=487) and unfractionated heparin (15%, n=97). Bridged patients were more likely to have had prior 
cerebrovascular events (22% versus 15%; P=0.0003) and mechanical valve replacements (9.6% versus 2.4%; P<0.0001); 
however, there was no difference in CHA2DS2-VASc scores (scores ≥2 in 94% versus 95%; P=0.5). Bleeding events were 
more common in bridged than nonbridged patients (5.0% versus 1.3%; adjusted odds ratio, 3.84; P<0.0001). The incidence 
of myocardial infarction, stroke or systemic embolism, major bleeding, hospitalization, or death within 30 days was also 
significantly higher in patients receiving bridging (13% versus 6.3%; adjusted odds ratio, 1.94; P=0.0001). 
Conclusions—Bridging anticoagulation is used in one quarter of anticoagulation interruptions and is associated with higher 
risk for bleeding and adverse events. These data do not support the use of routine bridging, and additional data are needed 
to identify best practices concerning anticoagulation interruptions.
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of embolic events during the interruption.3 Although guide-
lines have been published on when and how to initiate bridg-
ing therapy,4 they are based on limited data. Thus, it remains 
unclear whether patients who temporarily interrupt their anti-
coagulation should receive bridging anticoagulation.
We assessed the incidence of temporary interruption of OAC for 
procedures among a national outpatient AF registry. We specifically 
examined causes for the interruption of anticoagulation, the patterns 
of use of bridging anticoagulation agents (relative to underlying risk 
and current guidelines), and the outcomes among patients who were 
bridged compared with patients who were not bridged.
Methods
The Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation (ORIBT-AF) is a national, community-based registry of 
outpatients with AF. Eligible patients were enrolled by a nationally 
representative sample of primary care, cardiology, or electrophysiol-
ogy sites. An adaptive design was used to ensure heterogeneity of 
practice type and geography. Study coordination was managed by 
the Duke Clinical Research Institute. Major inclusion criteria were 
age of ≥18 years and ECG-documented AF that was not attributable 
to a reversible cause, and follow-up was to a maximum of 3 years. 
The ORBIT-AF registry has been described in detail previously.5 The 
present analysis includes patient data out to 2 years of follow-up.
Data collection was derived primarily from the patients’ medical 
records and included demographics, medical history, and AF history 
at baseline. Additionally, at baseline and every 6 months, investiga-
tors recorded medical and surgical therapies, vital signs, laboratory 
measurements, and echocardiographic data. The collection of medi-
cation data included the use and monitoring of OAC therapies. Sites 
were also instructed to enter which OAC treatment was used, as well 
as values for international normalized ratio monitoring when appli-
cable. At each follow-up, investigators were queried as to whether the 
patient temporarily interrupted OAC to undergo a procedure. Only 
interruptions for procedures were recorded; interruptions as a result 
of bleeding or other reasons are not captured. All medical manage-
ment around the procedure was guided entirely by the patient’s treat-
ment team. For such interruptions, we collected the date and type of 
procedure, use of bridging anticoagulant (defined as an anticoagulant 
temporarily administered in place of long-term therapy for the pur-
pose of stroke prevention before, during, or after the periprocedural 
period), and adverse events occurring during the interruption (bleed-
ing event, thrombotic event, or other event; no further specification 
was reported). Type of procedure was categorized as cardiac cath-
eterization, catheter ablation, endoscopy (gastrointestinal, broncho-
scopic, or genitourinary), cardiac surgery, noncardiac surgery (not 
further specified), device implantation, dental procedures, or other 
(not further specified). Bridging anticoagulant was categorized as 
low-molecular-weight heparin (LMWH), unfractionated heparin 
(UFH), fondaparinux, or other (not further specified).
Separately at each follow-up, investigators recorded the incidence 
and dates of any adverse events, including death, cause-specific hos-
pitalization (cardiovascular, bleeding, or other, as determined by the 
investigator), incident heart failure, myocardial infarction, stroke or 
systemic embolism (adjudicated by the coordinating center from 
primary source documentation), or major bleeding as defined by the 
International Society of Thrombosis and Haemostasis criteria.6
Analyzing Temporary Interruptions
The present analysis included only patients on OAC at baseline who 
had at least 1 follow-up visit. The study population was subsequently 
divided by incidence of interruption during follow-up: none versus any 
(≥1). The baseline characteristics of these patients were compared.
Subsequently, all interruption events were queried for the type of 
procedure requiring interruption and the use of bridging anticoagu-
lant. Additionally, the use of bridging anticoagulation was compared 
among high-risk subgroups. Among patients using warfarin, time to 
resumption of therapeutic international normalized ratio (≥2) was 
calculated. The use of bridging anticoagulation in the subgroup of 
patients receiving dabigatran was also described.
Adverse events occurring during the interruption of long-term 
anticoagulation (bleeding, thrombotic, or other [not further detailed]) 
are described and stratified by the use of any bridging anticoagulant 
versus none. The incidence and timing of adverse events occurring 
within 30 days after the date of the procedure for which there was an 
interruption are also described (and may overlap with those occurring 
during interruption); these include cause-specific hospitalization and 
the composite of myocardial infarction, stroke, major bleeding, hos-
pitalization, or death. The association of bridging with adverse events 
was assessed in a multivariable model of the composite outcome.
Statistical Methods
Comparisons between groups with no interruption and groups with any 
interruption are performed at the patient level. Comparisons between 
procedure types, bridging anticoagulant, and adverse events are per-
formed at the interruption level (a patient may have had >1 interrup-
tion during follow-up). In univariate analyses, categorical variables are 
presented as frequencies and percentages, and differences between 2 
groups are assessed by the χ2 test. Continuous variables are presented 
as median (quartiles 1–3) or mean (standard deviation), and differences 
between 2 groups are assessed by the Wilcoxon rank-sum test.
In analysis of adverse events within 30 days after interruption, mul-
tiple interruption events from the same patient were included unless the 
interruptions occurred within 30 days of a prior interruption. However, 
interruption events were excluded if the date was missing. To iden-
tify the association between the use of any bridging anticoagulant 
and adverse events, a multivariable model was developed. Covariates 
included age, estimated glomerular filtration rate, sex, prior cerebro-
vascular events, the presence of significant valvular disease or prior 
mechanical valve replacement, prior gastrointestinal bleeding, the 
presence of congestive heart failure, type of AF at baseline (new onset, 
paroxysmal, persistent, longstanding persistent), left atrial diameter 
size, patient level of education, CHADS2 score, the procedure requir-
ing interruption (with noncardiac surgery as the referent), and type of 
OAC at baseline (warfarin versus dabigatran; neither rivaroxaban nor 
apixaban was used in this cohort). The outcomes examined included 
any bleeding events (major bleeding or bleeding hospitalization); car-
diovascular events (stroke, systemic embolism, myocardial infarction, 
or cardiovascular hospitalization); and the composite of any myo-
cardial infarction, stroke or systemic embolism, any hospitalization, 
or death, all within 30 days after the date of the procedure requiring 
interruption. Adjusted odds ratios (ORs) were calculated from logis-
tic regression with the generalized estimating equation, which also 
accounted for correlations within the same patient.
The ORBIT-AF registry was approved by the institutional review 
board of Duke University, and each site received institutional review 
board approval subject to local requirements. All patients signed 
written, informed consent, and analyses of the aggregate, deidentified 
data were performed by the Duke Clinical Research Institute using 
SAS software (version 9.3, SAS Institute, Cary, NC).
Results
The overall ORBIT-AF population included 10 132 patients 
from 176 sites; 9642 patients had at least 1 follow-up visit. 
Excluding patients not on OAC at baseline (n=2270) yielded 
a final study cohort of 7372 patients. The median follow-up 
duration was 24 months. Overall, there were 2803 reported 
interruptions, the majority in noncardiac surgery (n=746, 
27%), other procedures (n=712, 25%), and endoscopy (n=504 
18%). Overall, 2138 interruptions (76%) did not use bridg-
ing anticoagulation, whereas 665 (24%) did. Distribution of 
bridging use by procedure is shown in the Figure.
Among the 665 interruption events that involved bridging 
anticoagulation, LMWH was used in 487 (73%), UFH in 97 
(15%), fondaparinux in 7 (1.1%), and another anticoagulant in 
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76 (11%). Twenty-three interruptions involving bridging were 
in patients treated with dabigatran at baseline: 12 used LMWH, 
6 used UFH, and 5 used other agents (none used fondaparinux).
A comparison of baseline characteristics between patients 
with no interruption (n=5172, 70%) and those with ≥1 inter-
ruption during follow-up (n=2200, 30%) stratified by bridging 
use is shown in Table 1. Compared with patients who did not 
have any interruption, those experiencing at least 1 interrup-
tion were slightly younger (median age, 75 versus 76 years; 
P=0.0002), more likely white (92% versus 89%; P=0.005), 
and less likely to have new-onset AF (2.6% versus 4.3%; 
P=0.0001) and had higher median calculated creatinine clear-
ance (71 versus 69 mL·min−1·1.72 m−2; P=0.002).7 Rates of 
prior coronary vascular or cerebrovascular disease, as well as 
mean CHADS2 scores, were all similar (P=NS for each). Of 
patients with at least 1 interruption, patients with any bridging 
interruption were statistically younger (median age, 74 versus 
75 years; P=0.009) and were more likely to have congestive 
heart failure (44% versus 34%; P<0.0001), prior cerebrovas-
cular events (22% versus 15%; P=0.0003), any valve disease 
(34% versus 27%; P=0.0006), and prior mechanical valve 
(9.6% versus 2.4%; P<0.0001) compared with patients who 
had at least 1 interruption but none with bridging. Baseline 
OAC also differed significantly (dabigatran in 3.7% versus 
6.8%; P=0.02). Although mean CHADS2 (2.53 versus 2.34; 
P=0.004) and CHA2DS2-VASc (4.25 versus 4.03; P=0.01) 
scores were higher in bridged patients, there were no differ-
ences in rates of CHADS2 score ≥2 (78% versus 76%; P=0.4) 
or CHA2DS2-VASc score ≥2 (94% versus 95%; P=0.5). Use 
of additional antiplatelet therapy was similar for concomitant 
single antiplatelet (39% versus 36%) and dual antiplatelet ther-
apy (3.0% versus 2.2%; P=0.2 across antiplatelet categories).
Among patients treated with warfarin who had at least 1 
follow-up international normalized ratio after the procedure 
(n=1452), time to the achievement of the therapeutic range (first 
international normalized ratio ≥2) after the procedure was sig-
nificantly shorter for interruptions with bridging compared with 
those without bridging (median, 17 versus 23 days; P<0.001).8
Outcomes
Unadjusted rates of individual outcomes during and after inter-
ruption are shown in Table 2. Events during interruption were 
relatively infrequent overall. Event rates were higher for inter-
ruptions in which bridging anticoagulation was used, includ-
ing any adverse event during interruption (5.3% versus 2.8%; 
P=0.01), major bleeding (3.6% versus 1.2%; P=0.0007), 
bleeding hospitalization (2.2% versus 0.7%; P=0.006), and 
cardiovascular hospitalization (4.2% versus 2.2%; P=0.02). 
Event counts and rates across different procedure types strati-
fied by bridging are shown in Table 3.
The association between bridging and adverse events per-
sisted in multivariate-adjusted analysis (Table 4): The use of 
bridging anticoagulation during interruption was significantly 
associated with an increase in bleeding events (adjusted OR, 
3.84 for major bleeding or bleeding hospitalization; 95% con-
fidence interval, 2.07–7.14; P<0.0001) and showed a trend 
toward increased cardiovascular events (adjusted OR, 1.62; 
95% confidence interval, 0.95–2.78; P=0.07). Overall, bridging 
was associated with an increased risk of adverse events, includ-
ing the composite of myocardial infarction, bleeding, stroke 
or systemic embolism, hospitalization, or death within 30 
days (adjusted OR 1.94; 95% confidence interval, 1.38–2.71; 
P=0.0001). The procedure for which the patient required inter-
ruption appeared to minimally influence composite adverse out-
comes (P=0.2 across all procedures); however, adverse events 
were significantly less common for dental procedures (adjusted 
OR, 0.19 versus noncardiac surgery; 95% confidence interval, 
0.06–0.63, Ppairwise=0.0063). Baseline anticoagulant (warfarin 
versus dabigatran) was not significantly associated with out-
comes after temporary interruption in the adjusted model.
In a sensitivity analysis that included baseline concomitant 
antiplatelet use (none, single, double), a consistent, significant 
association remained between bridging and adverse outcome.
Discussion
There are 3 major findings from this study. First, interruptions 
of OAC are common in contemporary patients with AF in 
clinical practice, often for cardiac procedures and noncardiac 
surgery, as well as for minimally invasive procedures. Second, 
in those temporary interruptions, bridging anticoagulation was 
used in approximately one quarter of patients, and the deci-
sion to use bridging appears to be guided by patient factors 
related to bleeding or thromboembolic risk. Finally, we found 
that the use of bridging anticoagulation was significantly asso-
ciated with higher overall bleeding and adverse event rates.
The rate of bridging anticoagulation was higher than that 
reported in contemporary trials.9 Patients with prior cerebrovas-
cular events, those with mechanical valves, and patients receiv-
ing warfarin (compared with dabigatran) were more likely 
to receive bridging anticoagulation, as would be expected. 
Additionally, bridging varied by type of procedure. These data 
generally reflect the limited guideline support for bridging, 
specifically that the decision for bridging in moderate- or high-
risk patients should be patient and procedure specific and that 
bridging in patients at low risk of thromboembolism should be 
avoided.4 Furthermore, the guidelines recommend more con-
servative management of bridging medications and call atten-
tion to scenarios in which OAC could be continued without 
Figure. Proportion of interruptions involving anticoagulant 
bridging by procedure. Endoscopy includes gastrointestinal, 
genitourinary, or bronchoscopic. cath indicates catheterization; 
and CV, cardiovascular.
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interruption (eg, dental procedures). Although this appears to 
demonstrate improvement in the previously described prac-
tice variability,10 room for further improvement remains, as 
indicated by the data in this study. Bridging anticoagulation 
appeared to be used more commonly than the guidelines would 
suggest. For example, we observed that a significant number 
of OAC interruptions were for dental procedures (n=239, 9% 
of all interruptions), and 8% of these temporary interruptions 
Table 1. Baseline Demographics, Medical History, and Laboratory Studies by Incidence of Temporary Interruption
No Temporary 
Interruption
(n=5172)
≥1 Temporary Interruptions
(n=2200)
Patients With ≥1  
Interruptions, None With 
Bridging (n=1608)
Patients With  
≥1 Interruptions With 
Bridging (n=592)
P Value,
No Bridging  
Versus Bridging
Age, y 76 (68–82) 75 (68–81) 74 (67–80) 0.009
Female, % 43 41 42 0.7
Race/ethnicity, % 0.1
  White 89 92 91
  Black 5.0 3.5 5
  Hispanic 4.6 3.7 2.7
  Other 1.5 1.2 0.5
AF type, % 0.5
  New onset 4.3 2.7 2.2
  Paroxysmal 46 46 48
  Persistent 19 16 17
  Long-standing persistent 31 35 32
CHADS
2 score, mean (SD) 2.4 (1.3) 2.34 (1.21) 2.53 (1.31) 0.004
CHA
2DS2-VASc score, mean (SD) 4.0 (1.7) 4.03 (1.62) 4.25 (1.74) 0.01
ATRIA score, mean (SD) 2.78 (1.89) 2.74 (1.94) 2.72 (1.95) 0.9
Prior cerebrovascular event, % 17 15 22 0.0003
Coronary artery disease, % 36 36 41 0.05
Congestive heart failure, % 34 34 44 <0.0001
Significant valve disease, % 27 27 34 0.0006
Moderate/severe mitral stenosis, % 1.7 1.1 2.5 0.01
Prior mechanical valve replacement, % 3.6 2.4 9.6 <0.0001
Prior GI bleeding, % 0.97
  Never 92 91 91
  >6 mo prior 6.9 1.4 1.5
  ≤6 mo prior 0.8 7.3 7.1
Baseline oral anticoagulant, % 0.02
  Warfarin 93 93 96
  Dabigatran 6.5 6.8 3.7
Most recent INR before the procedure, 
mean (SD)
… 2.34 (0.76) 2.28 (0.71) 0.3
Percentage of time with INR 2–3 before 
the procedure, %*
… 67 62 0.0002
Concomitant antiplatelet, %†
  Aspirin 36 36 38 0.4
  Clopidogrel 4.5 4.2 6.9 0.01
  Prasugrel 0.03 0.06 0 0.5
Calculated creatinine  
clearance, mL·min−1·1.73 m−2‡
69 (49–95) 71 (54–97) 70 (51–96) 0.3
LVEF, % 55 (50–60) 55 (50–60) 55 (45–60) <0.001
Values are presented as median (interquartile range) when appropriate. AF indicates atrial fibrillation; ATRIA, Anticoagulation and Risk Factors 
in Atrial Fibrillation; GI, gastrointestinal; INR, international normalized ratio; and LVEF, left ventricular ejection fraction.
*As calculated using the Rosendaal et al8 method.
†Including aspirin, clopidogrel, or prasugrel; no patient was on ticagrelor.
‡As calculated by the Cockcroft-Gault7 formula.
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involved the use of a bridging anticoagulant. Furthermore, there 
were excess adverse events in bridged patients undergoing spe-
cific procedures (eg, catheter ablation, endoscopy), indicating 
particularly unfavorable risk in these cases. Such management 
may contribute to worse clinical outcomes overall, and our data 
do not support the routine use of bridging in AF patients requir-
ing temporary interruption of anticoagulation.
Our data show that the risks associated with interruptions 
and the risk of bridging during them are not limited to the 
periprocedural period. Adverse events in patients interrupting 
OAC persist as late as 30 days and include bleeding events, 
thrombotic events, and recurrent hospitalizations. Although the 
use of bridging has been shown to be safe in closely controlled 
clinical trials,3,11 outcomes in the community, where protocols 
are often absent or inconsistent, have been more limited. They 
included heterogeneous patient cohorts anticoagulated for a 
variety of indications, and only bleeding and thromboembolic 
outcomes were reported.1,2
The most recent US national guidelines highlight the 
dearth of evidence for the practice12; furthermore, there 
is mounting evidence that certain procedures may be per-
formed more safely with anticoagulation uninterrupted.13,14 
Importantly, there is less experience with uninterrupted, 
direct-acting OACs in this setting.15,16 The risks of bridg-
ing likely highlight the challenges in managing patients on 
OAC in the periprocedural period. In the patient receiving 
bridging agents, both of the most common drugs (UFH and 
LMWH) require attention to dosing to prevent bleeding and 
to provide anticoagulant effect (UFH on a continuous basis; 
LMWH with changes in weight, kidney function, or in preg-
nancy). Additionally, many patients require transitions in 
anticoagulants at the same time they are experiencing a tran-
sition in care (eg, on admission, from the intensive care unit 
to the floor, or during discharge to another facility or home). 
Such circumstances likely contribute to an increased risk 
associated with the use of short-term anticoagulants. Close 
attention to anticoagulant transitions and dosing is vital to 
minimizing risk.17 Properly identifying the group of patients, 
Table 2. Unadjusted Outcomes During and After Temporary 
Interruption of OAC
Overall
(n=2280), 
% (n)
No Bridging  
(n=1766),  
% (n)
Bridging  
(n=514), 
% (n) P Value
Any adverse event during 
interruption
3.4 (77) 2.8 (50) 5.3 (27) 0.01
  Bleeding event 2.2 (50) 1.8 (31) 3.7 (19) 0.02
  Thrombotic event 0.6 (13) 0.5 (9) 0.8 (4) 0.5
  Other adverse event 0.6 (14) 0.6 (10) 0.8 (4) 0.6
Events within 30 d after the procedure requiring interruption*
  Myocardial infarction 0.2 (5) 0.2 (4) 0.2 (1) 0.9
  Stroke or systemic 
embolism
0.4 (8) 0.3 (5) 0.6 (3) 0.3
  Major bleeding 1.7 (38) 1.2 (20) 3.6 (18) 0.0007
  Hospitalization
   Cardiovascular 2.7 (59) 2.2 (38) 4.2 (21) 0.02
   Bleeding 1.0 (23) 0.7 (12) 2.2 (11) 0.006
   Other 3.1 (69) 2.8 (49) 4.0 (20) 0.2
  Death 0.2 (4) 0.2 (3) 0.2 (1) 0.9
OAC indicates oral anticoagulation.
*Denominators exclude interruptions missing date or those that occurred 
within 30 days of a previous interruption (n=2227 overall, 1724 without 
bridging, 503 with bridging). Events within 30 days of the procedure requiring 
interruption may overlap with those during interruption.
Table 3. Adverse Events Within 30 Days by Procedure Type 
and Bridging Anticoagulation
Cardiovascular  
Events, n (%)*
Bleeding  
Events, n (%)†
No Bridging 
(n=1724)
Bridging 
(n=503)
No Bridging 
(n=1724)
Bridging 
(n=503)
Catheterization/PCI 9/139 (6.5) 3/65 (4.6) 2/139 (1.4) 1/65 (1.5)
Catheter ablation 1/66 (1.5) 5/41 (12.2) 1/66 (1.5) 0/41 (0)
Endoscopic 
procedure
9/343 (2.6) 2/64 (3.1) 5/343 (1.5) 5/64 (7.8)
Cardiac surgery 3/48 (6.3) 2/28 (7.1) 2/48 (4.2) 2/28 (7.1)
Noncardiac surgery 6/410 (1.5) 2/149 (1.3) 5/410 (1.2) 12/149 (8.1)
Device implantation 9/139 (6.5) 2/38 (5.3) 0/139 (0) 0/38 (0)
Dental work 1/166 (0.6) 0/16 (0) 0/166 (0) 0/16 (0)
Other 5/413 (1.2) 7/102 (6.9) 7/413 (1.7) 5/102 (4.9)
Excluding interruptions missing a date or those that occurred within 30 days 
of a previous interruption. PCI indicates percutaneous coronary intervention.
*Includes stroke, systemic embolism, myocardial infarction, or cardiovascular 
hospitalization within 30 days of the procedure requiring interruption.
†Includes major bleeding or bleeding hospitalization within 30 days of the 
procedure requiring interruption.
Table 4. Adjusted 30-Day Outcomes by Use of Bridging 
Anticoagulation
Unadjusted, % (n) Adjusted*
No Bridging
(n=1724)
Bridging
(n=503) P Value
Adjusted OR  
(95% CI),  
Bridging Versus  
No Bridging P Value
Cardiovascular 
events†
2.5 (43) 4.6 (23) 0.02 1.62 (0.95–2.78) 0.07
Bleeding events‡ 1.3 (22) 5.0 (25) <0.0001 3.84 (2.07–7.14) <0.0001
Overall 
composite§
6.3 (108) 13 (64) <0.0001 1.94 (1.38–2.71) 0.0001
Denominators exclude interruptions missing a date or those that occurred 
within 30 days of a previous interruption. Events within 30 days of the procedure 
requiring interruption may overlap with those during interruption. CI indicates 
confidence interval; and OR, odds ratio.
*Adjustment model covariates included age, estimated glomerular filtration rate, 
sex, prior cerebrovascular events, the presence of significant valvular disease or 
prior mechanical valve replacement, prior gastrointestinal bleeding, the presence 
of congestive heart failure, type of atrial fibrillation at baseline (new onset, 
paroxysmal, persistent, long-standing persistent), left atrial diameter size, patient 
level of education, CHADS2 score, procedure requiring interruption (with noncardiac 
surgery as the referent), and type of oral anticoagulation at baseline (warfarin 
versus dabigatran; neither rivaroxaban nor apixaban was used in this cohort).
†Includes stroke, systemic embolism, myocardial infarction, or cardiovascular 
hospitalization within 30 days of the procedure requiring interruption.
‡Includes major bleeding or bleeding hospitalization within 30 days of the 
procedure requiring interruption.
§Includes the composite of stroke, myocardial infarction, major bleeding, 
hospitalization, or death within 30 days of the procedure requiring interruption.
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if any, in whom the risk of these pitfalls is outweighed by 
the benefit of OAC interruption and bridging remains a chal-
lenge. They are likely to include patients at extremely high 
risk of periprocedural thromboembolic events (eg, those with 
mechanical mitral valve prostheses) undergoing procedures 
for which uninterrupted, periprocedural anticoagulation is 
prohibitively dangerous (eg, neurological procedures).
Some have speculated that, in patients at lower risk of bleed-
ing, bridging may be worthwhile.11 However, in our cohort 
of AF patients, most of whom had low-risk Anticoagulation 
and Risk Factors in Atrial Fibrillation (ATRIA) bleeding 
scores, we found that bridging anticoagulation was still sig-
nificantly associated with worse clinical events at 30 days, 
particularly bleeding and bleeding hospitalizations. This said, 
the results here are observational, and we cannot rule out the 
beneficial role of bridging in select circumstances. The ongo-
ing Effectiveness of Bridging Anticoagulation for Surgery 
(BRIDGE) study, which randomized nearly 2500 warfarin-
treated patients undergoing surgery to either LMWH or pla-
cebo during the perioperative period, will provide additional 
insight (http://www.clinicaltrials.gov; NCT00786474).
Importantly, we also observed the use of bridging anticoag-
ulation in patients receiving the oral direct thrombin inhibitor 
dabigatran. Although guidelines on the use of novel OACs in 
the setting of procedures are limited,18 their pharmacokinet-
ics are such that bridging is likely redundant (although this 
remains to be proven in patients at high risk of thromboem-
bolic events). In contrast to warfarin, which requires several 
days both to take effect and to wash out, direct-acting antico-
agulants demonstrate short time to onset and are cleared rela-
tively quickly, similar to LMWHs. Thus, the use of bridging 
anticoagulants in such patients has been cautioned; however, 
additional studies are needed.9
Limitations
This analysis is derived from the ORBIT-AF registry, which 
is an observational study of real-world patients in community, 
clinical practice. Limitations of such a study include enroll-
ment or sampling biases and reporting bias. Because patients 
were not randomized either to the occurrence of an interrup-
tion or to the use of bridging, a causal relationship between 
these events and adverse outcomes cannot be confirmed. 
Furthermore, it is possible that postprocedure parenteral anti-
coagulation is a requirement of the procedure; thus, use of 
such an agent would occur regardless of whether a patient is 
on long-term OAC. Data for patients who undergo procedures 
without interruption and for those who interrupt anticoagula-
tion for reasons other than procedures are not available; thus, 
we cannot comment on the implications of our findings for 
these groups. Finally, despite statistical methods aimed at 
adjusting for baseline differences in the population, we cannot 
exclude residual or unmeasured confounding of the results.
Conclusions
Temporary interruptions are common in patients receiving 
OAC for AF and occur even for minimally invasive proce-
dures. Many patients receive bridging anticoagulation, and its 
use varies by procedure type and certain patient characteris-
tics. Use of bridging anticoagulation was associated with an 
increased risk of bleeding and adverse events after interrup-
tion. These data do not support the use of routine bridging 
in anticoagulated patients with AF, and additional data are 
needed to identify best practices concerning anticoagulation 
interruptions.
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CLINICAL PERSPECTIVE
Patients receiving oral anticoagulation often require temporary interruption of such therapy for invasive procedures. Often, 
bridging with short-acting anticoagulants is used; however, the safety and effectiveness of such an approach have not been 
proven. We assessed the association between bridging anticoagulation and clinical outcomes in patients with atrial fibrilla-
tion receiving anticoagulation that was temporarily interrupted for a procedure. Among 7372 community outpatients in the 
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry treated with oral anticoagula-
tion at baseline, 2803 overall interruption events occurred in 2200 patients (30%) at a median follow-up of 2 years. Bridging 
anticoagulants were used in 24% (n=665), most commonly with low-molecular-weight heparin (73%, n=487) and unfrac-
tionated heparin (15%, n=97). After adjustment for known confounders, bleeding events were more common in bridged than 
nonbridged patients (5.0% versus 1.3%; adjusted odds ratio, 3.84; P<0.0001). The incidence of myocardial infarction, stroke 
or systemic embolism, major bleeding, hospitalization, or death within 30 days was also significantly higher in patients 
receiving bridging (13% versus 6.3%; adjusted odds ratio, 1.94; P=0.0001). These data call into question the safety of rou-
tinely bridging patients on oral anticoagulation who require temporary interruption for a procedure. Additional prospective 
trials are necessary to identify in which patients, if any, the benefit of bridging outweighs the risk.
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